Cixutumumab in Combination with Temsirolimus in Recurrent or Refractory Solid Tumors

Children's Oncology Group (COG)


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors.

What is the trial about?

Find out if cixutumumab and temsirolimus can stop the cancer from growing or cause it to get smaller.

Who can participate?

> 12 months and < 30 yrs of age.

What is involved?

Participation through April 2014. Standard cancer care including tumor biomarker tests.

Contact Nemours Clinical Trials

Trial Name: A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors

COG#: ADVL1221

Contact Information

(800) 354-5690
clinicaltrials@nemours.org